



# Fast Regeneration Restored Motion


**Product Brochure** 

## **The Clinical Situations**

Clinical situations may be challenging. The patients you see on a daily basis require fast, effective treatment for a range of full-thickness wounds. Your goal is to help the patient to get back to normal life while managing the overall treatment costs.

## Challenges of full-thickness wound injuries and grafting:

- O Fast revascularization of grafts
- O Exposed tendon and bones
- O Patient functionality and scarring
- O Multiple operating-room requirements and procedures



A 42-year-old male presented with a flame burn, 42% TBSA on chest and neck. Early excision was performed on day four.\*



A 64-year-old female presented with an infected dog bite on the dorsum of the hand. After one month of pre-treatment in a general hospital, the wound bed was still necrotic.\*\*



A 60-year-old male with diabetic foot syndrome and a history of obesity and coronary heart disease, presented with a gangrenous right foot.\*



A 42-year old female presented with a basal cell carcinoma in the face. The cancer was excised widely, resulting in a deep dermal wound.\*\*

<sup>\*</sup> Courtesy of E. Dantzer, Toulon, France \*\* Courtesy of U. Hug, MD, Luzern, Switzerland

<sup>\*</sup> Courtesy of D. Luedi, Langenthal, Switzerland \*\* Courtesy of N. Lilgenau, MD, Vienna, Austria

# The Key Factor of the Success


The key factor of the MatriDerm<sup>®</sup> Dermal Matrix success is our Advanced CryoSafe<sup>™</sup> Method that preserves the native biological properties of the collagen elastin matrix.

### The MatriDerm® Dermal Matrix Mode of Action


MatriDerm® Dermal Matrix is a unique collagen elastin matrix, which serves as a dermal replacement scaffold.




In a cost-effective One-Step Procedure, MatriDerm® Dermal Matrix is placed on the wound bed and covered with a split-thickness skin graft.



MatriDerm® Dermal Matrix provides a native three-dimensional collagen elastin matrix to facilitate cell migration and guided healing.<sup>8, 10, 11</sup>



Fibroblasts are guided by the native collagen elastin scaffold ensuring structured healing and formation of a neo-dermis.<sup>8, 10, 11</sup>




Enhanced neo-angiogenesis and formation of microvessels ensuring supply and optimal split-thickness skin graft take. <sup>1, 5, 6, 7, 9, 14</sup>


# The MatriDerm® Dermal Matrix Difference

MatriDerm<sup>®</sup> Dermal Matrix is a unique collagen elastin matrix, which serves as a dermal replacement scaffold.







Human dermis



Other processed dermal matrix



MatriDerm® Dermal Matrix



STSG\*

Angiogenesis 15 days post implantation – courtesy of Prof. Kamolz, Austria

MatriDerm® Dermal Matrix

\* Split-thickness skin graf

## Why Processing Matters!

Structural integrity and biological activity of the collagen are highly dependent on differences in the manufacturing process.<sup>2</sup>

The unique MatriDerm<sup>®</sup> Dermal Matrix manufacturing process (Advanced CryoSafe<sup>™</sup> Method) preserves the native collagen triple helical structure as well as the cellular binding sites of its collagen products, which is important for the cellular interaction.<sup>2</sup>

#### The MatriDerm® Dermal Matrix Difference

#### Elastin

- O Triggers early vascularization 3, 4, 5, 19 and may reduce risk of infection (revascularization allows for white blood cells to migrate to the site) 18, 19
- Significantly improves skin elasticity (compared to split-thickness skin graft alone) 1, 5, 6, 7, 9
- Enables early physical therapy and rehabilitation<sup>20</sup>

#### One- and Multi-Step Procedure

- Can be used in a One-Step Procedure which saves time and money and enables an early patient mobilization
- If more than one step is needed the wound can already be grafted after 5-12 days

#### Native collagen fibers

- Guided healing to avoid unstructured scar tissue<sup>8,10,11</sup>
- Improved cell migration and reconstruction of new dermis 10,11

No chemical cross-linking

- O Non-release of cell-toxic substances
- O Improved cellular growth 12,13


## The Clinical Evaluation

Under clinical evaluation MatriDerm® Dermal Matrix has shown to be fast and effective in the management of a range of full-thickness wounds, helping patients back to normal life and reducing the overall cost of care.



#### Fast

Shorter healing period with MatriDerm® Dermal Matrix




Modified according to Jeon et al. 2013, n=60



## Cost effective

Total surgical treatment costs don't differ significantly from STSG\*



Surgical treatment of burns


Modified according to Hop et al. 2013, n = 43

\* Split-thickness skin graft



## Quality of life

Determination of skin elasticity via Cutometer® measurement




MatriDerm® Dermal Matrix 12 months post-op., III° burn wounds, n = 10 L.P. Kamolz, presentation ISBI Meeting Montreal 2008



## Effective

Improved efficacy with MatriDerm® Dermal Matrix



Post-traumatic injuries – take rate after 2 weeks Modified according to Cervelli et al. 2011, n=60

\* Split-thickness skin graft

# The Clinical Evaluation


The long-lasting effect on scar quality by the use of MatriDerm® Dermal Matrix, even after 12 years, has been shown by Bloemen et. al¹:

- o Improved scar parameter
- Improved scar appearance (cosmetic)

#### Burns\*



Intraoperative



Intraoperative after the application of MatriDerm® Dermal Matrix



3 years postoperative



3 years postoperative

#### Trauma\*\*



Intraoperative afterdebridement



Intraoperative after the application of MatriDerm® Dermal Matrix and mesh graft



Stable wound closure 3 months postoperative



Full extension 2 years postoperative

#### Chronic Wound\*



Preoperative



Intraoperative after the application of MatriDerm® Dermal Matrix and mesh graft



3 months postoperative



6 months postoperative

Cancer Excision\*\*



After excision



Intraoperative after the dry application of MatriDerm® Dermal Matrix



7 months postoperative



7 months postoperative

<sup>\*</sup> Courtesy of E. Dantzer, Toulon, France \*\* Courtesy of U. Hug, MD, Luzern, Switzerland

<sup>\*</sup> Courtesy of D. Luedi, Langenthal, Switzerland \*\* Courtesy of N. Lilgenau, MD, Vienna, Austria

# **Fast Regeneration Restored Motion**

- O Fast integration & revascularization3, 4, 5,10, 11
- O Effective closure of full-thickness injuries<sup>1, 7, 14</sup>
- O Cost-effective One-Step Procedure 15, 16
- O Superior functional & aesthetic outcomes<sup>1, 7, 17</sup>

		Ref. No.	Size
	A4	83500 - 200	210 x 297 x 1 mm
1	A4	83400 - 200	210 x 297 x 2 mm
2	A6	83403 - 200	105 x 148 x 1 mm
	AO	83401 - 200	105 x 148 x 2 mm
	A8	83404 - 200	52 x 74 x 1 mm

74 mm

<b>A4</b> 623.7 cm <sup>2</sup>	
<b>A6</b> 155.4 cm <sup>2</sup>	
<b>A8</b> 38.48 cm <sup>2</sup>	



MedSkin Solutions Dr. Suwelack AG Josef-Suwelack-Strasse 2 48727 Billerbeck I Germany

+49 (0)2543 2182-0

info@medskin-suwelack.com

www.medskin-suwelack.com

#### References

- <sup>1</sup> Bloemen MC et al., Plast Reconstr Surg, 2010, 125(5):1450-9
- <sup>2</sup> Böhm S et al.; Materials 2017; 10(9), 1086 <sup>3</sup> Geyer et al., Annals of Anatomy (2015) 197, 3-10
- Wiedner M et al., Wound Repair Regen, 2014, 22(6):749-54
   Daamen WF et al., Tissue Eng, 2008, 14(3):349-60
   Haslik W et al., JPRAS, 2010, 63(2):360-4
   Ryssel H et al., Burns, 2008, 34(1):93-7

- <sup>8</sup> Scanning-Electron-Microscopy-images: © Dr. M. Mörgelin,
- University Lund, Sweden
  <sup>9</sup> Ryssel H. et al., Int Wound J., 2010, 7(5):385-92

- \*\*Olyssel H. et al., Mound Repair Regen, 1994, 2(1):37-47

  \*\*I'de Vries H et al., Br J Dermatol., 1995, 132(5):690-7

  \*\*Ellat J et al., Int J Mol Sci. 2013 Jul 11, 14(7):14460-74

  \*\*Willat J et al., Dissertation, Ludwigs-Maximilians-Universität München, 2016

  14 Cervelli V. et al., Int Wound J 2011, 8(4):400-5

- Hop M. et al., Burns 2013, 40(3):388-96
   Jeon H. et al., Arch Plast Surg 2013, 40(4):403-8
   Watfa W. et al., J Sex Med 2017, 14(10):1277-1284
- <sup>18</sup> Granick, M. S., Teot, L., informs Healthcare, second ed., CRC press 2012
   <sup>19</sup> Frueh F. S. et al., Journal of Investigative Dermatology (2017) 137, 217-227
- 20 Haslik et al., Burns 2007, 33(3): 364-8

All product and company names are trademarks<sup>™</sup> or registered<sup>®</sup> trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.